Poland· PL-100516804
Hetronifly
A serplulimab product containing serplulimabum, registered in Poland by Accord Healthcare S.L.U.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Serplulimab is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FF12 (serplulimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Serplulimab · ATC L01FF12
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Serplulimabum
- Manufacturer
- Accord Healthcare S.L.U.
- Country
- Poland (PL)
- ATC code
- L01FF12
- ATC class
- Serplulimab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05055565798140
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Serplulimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumHetronifly 10 mg/mlAccord Healthcare
- SwitzerlandHetronifly 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungAccord Healthcare AG
- CzechiaHETRONIFLYAccord Healthcare S.L.U., Barcelona
- FinlandHETRONIFLYAccord Healthcare S.L.U.
- IrelandHETRONIFLY 10 mg/ml concentrate for solution for infusionAccord Healthcare S.L.U.
- IcelandHETRONIFLYAccord Healthcare S.L.U.
- NorwayHetroniflyAccord Healthcare S.L.U.
- SwedenHETRONIFLY 10 mg/ml Koncentrat till infusionsvätska, lösningAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hetronifly
- Iceland · Hetronifly
- Liechtenstein · Hetronifly
- Norway · Hetronifly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/14f6f9c5-c321-452a-8103-beccdb18a2e7 GET /v1/drugs/14f6f9c5-c321-452a-8103-beccdb18a2e7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "05055565798140 ¦ Rpz ¦ EU/1/24/1870/001 ¦ 161465\n1 fiol. 10 ml",
"substance": "Serplulimabum 10 mg/ml",
"common_name": "Serplulimabum",
"pl_product_id": "100516804",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about serplulimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.